to be honest had the same thoughts, but the market unlikely to have read the announcement. The survival benefit is clear per the chart, whereas the ALSFR-S chart would just show the movements. I think that is why it’s left out nothing more
If certain patients had seen a rapid decline that may not be unexpected given the sporadic nature of the disease. Removing any declining outliers would actually suggest the other patients responded even better. This is because the outliers would in effect bring down the average.
Don’t think we need anymore detail for the moment, if a patient passed the survival graph would have dipped it didn’t. The genetic biomarker info is all part of the data pack needed for FDA and Pharma.
Just look at the bigger picture everything seems to be going well with the OLE and gets better everyday that passes.
- Forums
- ASX - By Stock
- NUZ
- Ann: Positive 8-month Interim Data from OLE Study
NUZ
neurizon therapeutics limited
Add to My Watchlist
3.23%
!
16.0¢

Ann: Positive 8-month Interim Data from OLE Study, page-53
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
16.0¢ |
Change
0.005(3.23%) |
Mkt cap ! $78.76M |
Open | High | Low | Value | Volume |
15.5¢ | 16.0¢ | 15.0¢ | $78.77K | 503.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 240870 | 15.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 377391 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 240870 | 0.150 |
7 | 1185247 | 0.145 |
7 | 145632 | 0.140 |
5 | 146261 | 0.135 |
1 | 10000 | 0.125 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 377391 | 2 |
0.165 | 118100 | 2 |
0.170 | 16335 | 2 |
0.175 | 6045 | 1 |
0.180 | 251616 | 3 |
Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
Featured News
NUZ (ASX) Chart |